Collegium Pharmaceutical (COLL) Projected to Post Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is expected to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Collegium Pharmaceutical to post earnings of $1.52 per share and revenue of $184.47 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The firm had revenue of $205.45 million for the quarter, compared to the consensus estimate of $206.36 million. During the same quarter in the prior year, the firm earned $1.77 earnings per share. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Collegium Pharmaceutical Stock Up 0.5%

Shares of NASDAQ COLL traded up $0.19 during mid-day trading on Wednesday, hitting $35.51. 72,199 shares of the stock traded hands, compared to its average volume of 496,878. The company has a debt-to-equity ratio of 2.59, a quick ratio of 1.48 and a current ratio of 1.57. Collegium Pharmaceutical has a 52 week low of $26.72 and a 52 week high of $50.79. The company has a market cap of $1.15 billion, a price-to-earnings ratio of 20.74 and a beta of 0.76. The stock has a fifty day moving average price of $35.63 and a 200-day moving average price of $41.56.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the sale, the executive vice president directly owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This trade represents a 41.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP David Dieter sold 13,976 shares of the stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total value of $488,041.92. Following the sale, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 1.85% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the business. Voleon Capital Management LP purchased a new stake in shares of Collegium Pharmaceutical during the third quarter valued at $381,000. State of Wyoming boosted its position in shares of Collegium Pharmaceutical by 113.9% during the second quarter. State of Wyoming now owns 12,297 shares of the specialty pharmaceutical company’s stock valued at $364,000 after buying an additional 6,547 shares during the last quarter. Corient Private Wealth LLC increased its position in Collegium Pharmaceutical by 10.8% during the fourth quarter. Corient Private Wealth LLC now owns 7,768 shares of the specialty pharmaceutical company’s stock valued at $360,000 after acquiring an additional 760 shares during the last quarter. Sei Investments Co. increased its position in Collegium Pharmaceutical by 5.5% in the second quarter. Sei Investments Co. now owns 11,436 shares of the specialty pharmaceutical company’s stock worth $338,000 after buying an additional 600 shares in the last quarter. Finally, Atom Investors LP grew its position in shares of Collegium Pharmaceutical by 5.0% during the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 294 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Barclays dropped their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $53.40.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.